Back to search

Democritus University of Thrace (DUTH)

Μελέτη της ανοσολογικής απόκρισης ποντικών ανοσοποιημένων με εμβόλια γενετικού υλικού που στοχεύουν επιλεγμένα καρκινικά αντιγόνα

Abstract

dc:description

Cancer is a leading cause of mortality worldwide, and conventional therapies, including surgery, radiation and chemotherapy are highly invasive without offering lifelong protection. Nowadays it is believed that the immune system is one of the major players in cancer development, since it became clear that tumors evade immune surveillance and destruction and they co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells specific for tumor antigens. Thus, immunotherapy has received increasing attention over the last few decades as a strategy for cancer treatment and new immunotherapeutic approaches have been developed that are positively influencing clinical outcome for cancer patients. The goal of immunotherapy is to harness the immune system to elicit specific immune responses against tumor-associated antigens (TAAs). In this context, DNA vaccination represents a promising strategy for harnessing the immune system to fight cancer. DNA vaccines are easy to construct and store, low-priced, safe and reproducible. Cancer DNA vaccines are designed to deliver one or several genes encoding tumor antigens or to modulate immune responses, thereby eliciting or augmenting immune responses against tumor antigens that play central role in tumor initiation, progression and metastasis. Vaccine efficacy can be significantly improved not only through selection of appropriate tumor antigens, moreover, by implementing strategies for improving antigen presentation and immunogenicity. Cancer DNA vaccines can induce both innate immunity activation and adaptive immune responses in order to suppress tumor growth and achieve total tumor rejection. New developments in vaccine delivery methods improve the efficiency of tumor antigens to evoke immune responses with the aim to overcome the primary hurdle of poor transfection efficacy and subsequent lower immunogenicity. DNA vaccines are usually administered intramuscularly or intradermal. Muscle and skin cells are able to accumulate antigens, but unable to prime immune responses. Recombinant plasmids that enter somatic cells are directed to the nucleus and express the encoded genes. Produced antigens are presented through MHC class I molecules to CD8 T cells. In intramuscular administration, most of the vaccine is received by the muscle cells. Synthesized proteins are released in the extracellular matrix and are endocytosed or phagocytosed and displayed by antigen-presenting cells through MHC class II molecules to activate CD4 T helper cells in the presence of costimulatory signals. Activated B cells differentiate into plasma cells and secrete antibodies that bind antigenic epitopes. The antigenic peptides that have remained in the cytoplasm of the targeted cells are initially presented via MHCI molecules and activate cytotoxic CD8 T cells. When the vaccine is administered intradermally, DNA enters the skin and dendritic cells, such as Langerhans cells, present antigens. Death of the antigen expressing cells increases antigen presentation and causes enhanced Th1 response.The present study aimed to design, develop and evaluate a new DNA vaccine to treat breast adenocarcinoma in a syngeneic experimental cancer model in BALB/c mice. Among the variety of tumor associated antigens, BIRC5, EpCAM and the novel NPTN were initially selected. DNA vaccine vectors were constructed and the selected antigens were expressed in cancer cell lines in vitro and in murine tissue in vivo. Our first experimental data and extensive literature search resulted in the selection of the cell adhesion molecule NPTN -neuroplastin- as a new promising tumor antigen.Neuroplastin is a transmembrane glycoprotein which exists in two isoforms. It belongs to the immunoglobulin superfamily of cell adhesion molecules (CAMs). In adults, NPTN is expressed almost exclusively in the immune "privileged" site of brain. Neuroplastin was recently identified as a novel breast cancer tumor associated antigen. Additionally, neuroplastin expression was detected in breast cancer cell lines and breast biopsies of advanced stage carcinomas.In order to examine the protective effect of neuroplastin DNA vaccine against breast adenocarcinoma, an experimental BALB/c syngeneic breast cancer model was established. 5x106 DA3 murine breast cancer cells were injected subcutaneously and tumor development was observed. One week later mice were euthanized; blood, tumor and spleen were collected. Tumor volume was calculated by the use of the modified ellipsoid formula (length*width2)/2. Neuroplastin protective efficacy was evaluated upon intra ear pinna vaccination. Vaccination (50mg) was performed for three times with 7 days interval. Mice were challenged with DA3 cells 3-5 days following the last immunization.DNA vaccines encoding neuroplastin, elicited protective immunity in BALB/c mice. Most NPTN-immunized mice did not develop tumors or if so, the developed tumors had statistically lower tumor volume compared to non-vaccinated mice or mice vaccinated with the vector alone. Interestingly, tumors isolated from immunized mice presented low expression level of the tumor antigens EpCAM and NPTN compared to control mice.The Neuroplastin DNA vaccine successfully raised antigen-specific immune responses in immunized BALB/c mice. NPTN-specific antibodies were detected both by confocal fluorescence microscopy and ELISA following immunization of mice (before or after tumor challenge). Sera were assayed as a source of primary anti-NPTN antibodies. Specific antibody titer in sera from immunized mice was comparable to the titer of the commercially available anti-NPTN antibody.Furthermore, the neuroplastin-specific immune responses were evaluated. Spleens were harvested from immunized mice and splenocytes were cultured and stimulated with four different antigenic neuroplastin peptides or their combination. Peptides were selected based on their capability to be presented by MHCI molecules to CD8+ T cells. Therefore 9mer peptides were selected using SYFPEITHI and IEDB databases designed for presentation by H2-Kd and H2-Ld MHC molecules of BALB/c mice. Culture supernatant of stimulated splenocytes was assayed by ELISPOT and IFN-γ production from many different clones of antigen-specific CD8+ cells was detected. The experimental data support the development of a CD8+ T cell cytotoxic immune response. Analysis of the antibody isotypes of sera from immunized or non-immunized BALB/c mice showed an increase in IgG2b and IgG3 isotype levels and a reduction in IgG1 antibodies. The observed immunoglobulin class switch is associated with a Th1 immune response. In addition, IL-12/IL-23 p40 and TNFa levels were significantly increased in the group of NPTN immunized mice, as confirmed by ELISA. Flow cytometry experiments revealed high CD8+ T cell infiltration of tumors and spleens of the immunized mice, which is consistent with IFN-γ production, cytotoxic response and the overall cytokine expression pattern.Our data suggest that a neuroplastin encoding DNA vaccine offer protective immunity in BALB/c mice with syngeneic breast adenocarcinoma without signs of autoimmunity. Mice raised NPTN-specific antibodies and vaccination promoted a cytotoxic Th1 immune response, as documented by isotype switch, cytokine profile and tumor infiltration of lymphocytes.Further investigation of neuroplastin role and the molecular signaling pathway could lead to the discovery of important target molecules involved in carcinogenesis. Early experiments showed that in vitro overexpression of neuroplastin leads to transcriptional activation of genes associated with angiogenesis and metastasis. Also, using an in vitro migration assay we showed that NPTN overexpression increased the migratory potential of HeLa cancer cells. The ultimate goal of our study is to further translate our findings into clinical practice in order to develop effective and specific protective immunity against mammary carcinoma in breast cancer patients.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tiptiri-Kourpeti, Angeliki
  • Τιπτιρή-Κουρπέτη, Αγγελική

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37913

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tiptiri-Kourpeti, Angeliki; Τιπτιρή-Κουρπέτη, Αγγελική. Μελέτη της ανοσολογικής απόκρισης ποντικών ανοσοποιημένων με εμβόλια γενετικού υλικού που στοχεύουν επιλεγμένα καρκινικά αντιγόνα. Democritus University of Thrace (DUTH), 2016. http://hdl.handle.net/10442/hedi/37913